Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Mink Intersects 7.1 Meters of 0.44% Ni, 0.28% Cu, 0.06% Co in Massive Sulphide at Warren Property (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Kamada Ltd KMDA

Healthcare Drug Manufacturers - Specialty & Generic
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus... see more

Recent & Breaking News (NDAQ:KMDA)

Kamada Reports Record Top- and Bottom-line 2025 Financial Results and Affirms 2026 Guidance Representing Continued Double-Digit Organic Profitable Growth

GlobeNewswire 14 hours ago

Kamada Declares Cash Dividend of $0.25 Per Share, to be Paid in Accordance with an Adopted Annual Cash Dividend Policy

GlobeNewswire 14 hours ago

Kamada to Announce Fiscal Year and Fourth Quarter 2025 Financial Results on March 11, 2026

GlobeNewswire 7 days ago

Kamada Targets 13% Revenue Growth And 23% Adjusted EBITDA Growth In 2026 Driven By Its Diverse Commercial Portfolio

TheNewsWire January 13, 2026

Kamada Provides 2026 Annual Guidance of $200 - $205 Million in Revenues and $50 - $53 Million of Adjusted EBITDA, Representing Double-Digit Growth and Affirms 2025 Financial Guidance

GlobeNewswire January 7, 2026

Kamada Announces a $10-$14 Million Extension of Canadian Supply Tender

GlobeNewswire December 18, 2025

Kamada Announces Discontinuation of its Phase 3 Inhaled AAT Clinical Trial; Reiterates 2025 Full-Year Guidance and Projects Double-Digit Growth in Revenues and Profitability in 2026

GlobeNewswire December 8, 2025

Kamada Reports Strongest Quarter For The Year In Q3, With Over 30% Profitability Increase Year-Over-Year

TheNewsWire November 18, 2025

Kamada Reports Strong Third Quarter and Nine Month 2025 Financial Results with over 30% Year-over-Year Profitability Growth

GlobeNewswire November 10, 2025

Kamada Announces First Patient Enrolled into an Investigator-Initiated Clinical Trial of CYTOGAM® to Prevent Cytomegalovirus in Kidney Transplantation

GlobeNewswire November 4, 2025

Kamada to Announce Third Quarter and Nine Months Ended September 30, 2025 Financial Results on November 10, 2025

GlobeNewswire November 3, 2025

Kamada to Present at the Stifel 2025 Healthcare Conference

GlobeNewswire October 29, 2025

Kamada to Participate in Upcoming September Investor Conferences

GlobeNewswire September 2, 2025

Kamada Reports Strong Second Quarter and First Half 2025 Financial Results with 11% Year-Over-Year 6-Month Top Line Growth and a 35% Increase in Profitability; Raises Full-Year Profitability Guidance

GlobeNewswire August 13, 2025

Kamada Announces FDA Approval of its Plasma Collection Center in Houston, Texas

GlobeNewswire August 11, 2025

Kamada to Announce Second Quarter and First Half Ended June 30, 2025 Financial Results on August 13, 2025

GlobeNewswire August 6, 2025

Kamada Confirms Continuous Global Business Operations and Products Availability Despite Recent Events in the Middle East

GlobeNewswire June 17, 2025

Kamada Q1 Results: Double-Digit Growth, Company Reiterates Guidance As It Hits Multiple Milestones Including Plasma Business Expansion

TheNewsWire June 11, 2025

Kamada Wants To Do More For Organ Transplant Patients, Increases Efforts To Build Awareness Of Its CMV Treatment CYTOGAM

TheNewsWire June 6, 2025

Kamada Reports Strong First Quarter 2025 Financial Results with Year Over Year Top Line Growth of 17% and a 54% Increase in Profitability

GlobeNewswire May 14, 2025

Podcasts